Cadence Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cadence Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-260,046	Closed	-$1.55M	–	716
2017 Q4	$1.55M	Buy	260,046 +18,770	+8%	+$114K	0.1%	276
2017 Q3	$1.78M	Buy	241,276 +48,863	+25%	+$310K	0.11%	214
2017 Q2	$1.31M	Buy	192,413 +79,500	+70%	+$587K	0.09%	288
2017 Q1	$1.07M	Buy	112,913 +46,365	+70%	+$463K	0.07%	335
2016 Q4	$575K	Sell	66,548 -121,751	-65%	-$900K	0.04%	483
2016 Q3	$1.19M	Sell	188,299 -4,376	-2%	-$26.5K	0.09%	267
2016 Q2	$813K	Buy	192,675 +37,048	+24%	+$179K	0.06%	345
2016 Q1	$679K	Buy	155,627 +27,610	+22%	+$123K	0.05%	407
2015 Q4	$785K	Sell	128,017 -21,136	-14%	-$139K	0.05%	369
2015 Q3	$853K	Sell	149,153 -14,507	-9%	-$111K	0.06%	333
2015 Q2	$1.22M	Buy	+163,660	New	+$990K	0.07%	365

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Cadence Capital Management's PGNX Position: Q1 2018 in Review

Cadence Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 260,046 shares — an estimated $1.55M sold.

Cadence Capital Management first reported a position in PGNX in Q2 2015 and held it in 11 quarters. The position peaked at $1.78M in Q3 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

Cadence Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
Cadence Capital Management sold 260,046 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $1.55M.
Cadence Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 11 quarters.
Cadence Capital Management's Progenics Pharmaceuticals Inc position peaked at $1.78M in Q3 2017.
152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on Cadence Capital Management's 13F filing for Q1 2018, filed 14 May 2018.